Search

Displaying results 1711 - 1720 of 5302 in total
  1. Drug

    Human papillomavirus type 33 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10311
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 33.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  2. Drug

    Human papillomavirus type 45 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10312
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 45.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  3. Drug

    Human papillomavirus type 58 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10314
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 58.

    Mixtures: GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO, GARDASIL® 9 VACUNA RECOMBINANTE NONAVALENTE CONTRA EL VIRUS DEL PAPILOMA HUMANO
  4. Drug

    Lyme disease vaccine (recombinant OspA)

    go.drugbank.com/drugs/DB00045
    ApprovedWithdrawn

    It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

  5. Drug

    Lipoic acid

    go.drugbank.com/drugs/DB00166
    ApprovedInvestigationalNutraceutical

    A vitamin-like antioxidant.

    Mixtures: Vita-Rx Diabetic Vitamin, Vita-Rx Diabetic VitaminProducts: LIPO-X (ALPHA LIPOIC ACID 50MG)
  6. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy

  7. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    It is an attractive target for immunotherapy.

  8. Drug

    EF-022

    go.drugbank.com/drugs/DB17768
    Investigational

    EF-022 is a modified version of vitamin D binding protein macrophage activator, with potential antineoplastic and anti-angiogenic activities.

    Synonyms: EF 022
  9. Drug

    Gatipotuzumab

    go.drugbank.com/drugs/DB18861
    Investigational

    Gatipotuzumab is under investigation in clinical trial NCT01899599 (Pankomab-gex™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer).

    Synonyms: Immunoglobulin g1, anti-(mucin muc1) (human-mus musculus monoclonal pankomab-gex heavy chain), disulfide with human-mus musculus monoclonal pankomab-gex light chain, dimer
  10. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference. Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to ...